Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DOTATOC in SSTR-positive tumours
2024-519183-40-00Phase 2Authorised
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Jan 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate in apudoma (NET), pheochromocytoma, Paraganglioma (PGL) and 2 more, sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Disease control rate at first evaluation. Planned start Jan 2025; status: authorised.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
apudoma (NET)pheochromocytomaParaganglioma (PGL)bronchial neuroendocrine tumorNonhematologic neoplasms
Beyond the preview
Go deeper on 2024-519183-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519183-40-00.